Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020
With much-awaited approval of biosimilar interchangeability by FDA, the dynamics in the much nascent US biosimilars market is about to change with long-lasting price competition. The report “Global Biosimilar Market by Classes (Insulin, Erythropoietin (EPO), Human Growth Hormone (HGH), Granulocyte- Colony Stimulating Factor (G-CSF), Monoclonal Antibody (mAb) and Interferon (IFN) & Markets (Developed & Emerging)- Industry Outlook 2020” provides an in-depth analysis of global biosimilars market focusing on key segments detailing approved and upcoming biosimilar products. Market outlook for aforementioned biosimilar classes has been provided for the period 2017-20.
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level. The report has been segmented as following:-
Market Segmentation by Classes
The report provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. Furthermore, the study encompasses various market specific growth opportunities at the global and regional level. The report has been segmented as following:-
Market Segmentation by Classes
- Insulin
- Erythropoietin (EPO)
- Human Growth Hormone (HGH)
- Granulocyte- Colony Stimulating Factor (G-CSF)
- Monoclonal Antibody (mAb)
- Interferon (IFN)
- Developed Markets – Europe and the US
- Emerging Markets – China & India
- Sandoz
- Hospira
- TEVA
- Celltrion
- Biocad
- Dong-A Pharmaceutical Co., Ltd.
- Stada
1. EXECUTIVE SUMMARY
2. RESEARCH METHODOLOGY
3. INTRODUCTION
4. GLOBAL BIOLOGICS MARKET
4.1 OVERVIEW
4.1.1 Classification of Biologics
4.2 GLOBAL BIOLOGICS MARKET ANALYSIS
1.1.1 Market Sizing (Actual & Forecasted)
5. GLOBAL BIOSIMILARS MARKET
5.1 OVERVIEW
5.2 MARKET ANALYSIS
5.2.1 Market Sizing (Actual & Forecasted)
2.1.1 Market Share by Region (Actual & Forecasted)
3.1.1 Market Share by Application (Actual & Forecasted)
4.1.1 Market by Product Pipeline
6. GLOBAL BIOSIMILARS MARKET SEGMENTATION
6.1 ERYTHROPOIETIN (EPO)
6.1.1 Overview
6.1.2 Market Analysis
6.2 INSULIN
6.2.1 Overview
6.2.2 Market Analysis
6.3 HUMAN GROWTH HORMONE (HGH)
6.3.1 Overview
6.3.2 Market Analysis
6.4 GRANULOCYTE- COLONY STIMULATING FACTOR (G-CSF)
6.4.1 Overview
6.4.2 6.4.2 Market Analysis
6.4.2 6.4.2 Market Analysis
6.5 MONOCLONAL ANTIBODY (MAB)
6.5.1 Overview
6.5.2 Market Analysis
6.6 INTERFERON (IFN)
6.6.1 6.6.1 Overview
6.6.2 Market Analysis
7. GLOBAL BIOSIMILARS MARKET ANALYSIS – DEVELOPED & EMERGING NATIONS
7.1 DEVELOPED MARKET
7.1.1Europe
7.1.2 The US
7.2 EMERGING MARKET
7.2.1 China
7.2.2India
8. GLOBAL BIOSIMILARS – PRICING ANALYSIS
9. GLOBAL BIOSIMILAR INDUSTRY – SWOT ANALYSIS
10. GLOBAL BIOSIMILARS MARKET ATTRACTIVENESS INDEX
11. GLOBAL BIOSIMILARS MARKET DYNAMICS
11.1 INDUSTRY TRENDS & DEVELOPMENTS
11.1.1 New Biosimilars Dominated by Large Globals
11.1.2 11.1.2 Biosimilar Interchangeability Guidance by FDA
11.1.3 11.1.3 Focus on Pharmerging Markets
11.2 GROWTH DRIVERS
11.2.1 11.2.1 Biological Patent Expiries
11.2.2 11.2.2 Cost saving
11.2.3 11.2.3 Increased use for Treatment of Chronic Diseases
11.3 CHALLENGES
11.3.1 11.3.1 High Cost of Development
11.3.2 11.3.2 Regulatory Uncertainty
11.3.3 11.3.3 Lower Adoption Rate of Biosimilars
11.3.4 11.3.4 Manufacturer Skills Gap
12. COMPETITIVE LANDSCAPE
12.1 MARKET SHARE BY COMPETITORS
12.2 MARKET SHARE BY DRUGS
13. COMPANY PROFILES
13.1 SANDOZ
13.2 HOSPIRA
13.3 TEVA
13.4 CELLTRION
13.5 BIOCAD
13.6 DONG-A PHARMACEUTICAL CO., LTD
13.7 STADA
2. RESEARCH METHODOLOGY
3. INTRODUCTION
4. GLOBAL BIOLOGICS MARKET
4.1 OVERVIEW
4.1.1 Classification of Biologics
4.2 GLOBAL BIOLOGICS MARKET ANALYSIS
1.1.1 Market Sizing (Actual & Forecasted)
5. GLOBAL BIOSIMILARS MARKET
5.1 OVERVIEW
5.2 MARKET ANALYSIS
5.2.1 Market Sizing (Actual & Forecasted)
2.1.1 Market Share by Region (Actual & Forecasted)
3.1.1 Market Share by Application (Actual & Forecasted)
4.1.1 Market by Product Pipeline
6. GLOBAL BIOSIMILARS MARKET SEGMENTATION
6.1 ERYTHROPOIETIN (EPO)
6.1.1 Overview
6.1.2 Market Analysis
6.2 INSULIN
6.2.1 Overview
6.2.2 Market Analysis
6.3 HUMAN GROWTH HORMONE (HGH)
6.3.1 Overview
6.3.2 Market Analysis
6.4 GRANULOCYTE- COLONY STIMULATING FACTOR (G-CSF)
6.4.1 Overview
6.4.2 6.4.2 Market Analysis
6.4.2 6.4.2 Market Analysis
6.5 MONOCLONAL ANTIBODY (MAB)
6.5.1 Overview
6.5.2 Market Analysis
6.6 INTERFERON (IFN)
6.6.1 6.6.1 Overview
6.6.2 Market Analysis
7. GLOBAL BIOSIMILARS MARKET ANALYSIS – DEVELOPED & EMERGING NATIONS
7.1 DEVELOPED MARKET
7.1.1Europe
7.1.2 The US
7.2 EMERGING MARKET
7.2.1 China
7.2.2India
8. GLOBAL BIOSIMILARS – PRICING ANALYSIS
9. GLOBAL BIOSIMILAR INDUSTRY – SWOT ANALYSIS
10. GLOBAL BIOSIMILARS MARKET ATTRACTIVENESS INDEX
11. GLOBAL BIOSIMILARS MARKET DYNAMICS
11.1 INDUSTRY TRENDS & DEVELOPMENTS
11.1.1 New Biosimilars Dominated by Large Globals
11.1.2 11.1.2 Biosimilar Interchangeability Guidance by FDA
11.1.3 11.1.3 Focus on Pharmerging Markets
11.2 GROWTH DRIVERS
11.2.1 11.2.1 Biological Patent Expiries
11.2.2 11.2.2 Cost saving
11.2.3 11.2.3 Increased use for Treatment of Chronic Diseases
11.3 CHALLENGES
11.3.1 11.3.1 High Cost of Development
11.3.2 11.3.2 Regulatory Uncertainty
11.3.3 11.3.3 Lower Adoption Rate of Biosimilars
11.3.4 11.3.4 Manufacturer Skills Gap
12. COMPETITIVE LANDSCAPE
12.1 MARKET SHARE BY COMPETITORS
12.2 MARKET SHARE BY DRUGS
13. COMPANY PROFILES
13.1 SANDOZ
13.2 HOSPIRA
13.3 TEVA
13.4 CELLTRION
13.5 BIOCAD
13.6 DONG-A PHARMACEUTICAL CO., LTD
13.7 STADA
